There are hopes a deal can be reached between the HSE and the pharmaceutical company behind a life saving Cystic Fibrosis drug.
There are hopes a deal can be reached between the HSE and the pharmaceutical company behind a life saving Cystic Fibrosis drug.
Vertex's under mounting pressure to lower the cost of 'Orkambi' – after trying to charge 160,000 euro per patient per year for the treatment.
Last night the firm said it would go back to talks with the HSE on the price of the medication.
CEO of Cystic Fibrosis Ireland Phillip Watt says the ball is now in their court.
